Vertex
Precision medicine company focused on cystic fibrosis, pain, and genetic disease programs.
Typical Backgrounds
Types of experience professionals commonly develop
Roles Companies Often Recruit
Common roles when hiring Vertex-caliber talent
- Principal Scientists
- Clinical Development Leaders
- Regulatory Affairs
- Medical Science Liaisons
- Bioinformatics Scientists
- Executive Leadership
Related Resources
Salary guides, hiring guides, market reports and case studies
Vertex as the model for precision-medicine focus
Vertex is the clearest example in biopharma of deep, narrow disease-area focus paying off: its cystic fibrosis franchise effectively transformed the disease's prognosis and generated the cash flow to fund newer bets in pain, type 1 diabetes cell therapy, and gene-editing therapies through its Casgevy partnership with CRISPR Therapeutics. That focus produces talent with unusually deep small-molecule and, increasingly, cell and gene therapy expertise.
Recruits Lab sees strong demand for Vertex alumni in both small-molecule discovery chemistry and, more recently, cell and gene therapy regulatory affairs following Casgevy's approval, since that program represents one of the first commercial gene-editing therapies and the regulatory playbook behind it is genuinely novel.
Org structure and titles that matter
Vertex organizes around Research (small-molecule and cell/gene therapy discovery), Clinical Development by program, Regulatory Affairs, and Commercial. Titles to know: Director and Senior Director of Chemistry within a discovery program, Executive Director of Clinical Development for cystic fibrosis or newer franchises, Director of Regulatory Affairs for Cell and Genetic Therapies (a distinct sub-function given Casgevy), and Director of Global Market Access.
Because Vertex runs a genuinely narrow portfolio relative to its size, its Directors often carry program-level P&L visibility that is closer to a smaller biotech's structure than a typical large-pharma matrix.
Hiring bar and interview process
Vertex's interviews are scientifically intensive, particularly for discovery chemistry roles, often including a data presentation defended in front of a multidisciplinary panel spanning chemistry, biology, and DMPK. The company is known for hiring people who can defend molecule-design tradeoffs rigorously, reflecting its history of iterating through multiple CFTR modulator generations before achieving triple-combination therapy.
Clinical and regulatory interviews for the cell and gene therapy group probe comfort with genuinely novel regulatory pathways, since Casgevy's approval required navigating precedent-setting FDA and EMA review processes.
Compensation posture
| Level / Function | Typical Total Comp Range | Equity Form | Notes |
|---|---|---|---|
| Senior Director, Discovery Chemistry | $250K–$320K | Vertex RSUs | Iterative small-molecule program experience is a differentiator |
| Director, Regulatory Affairs (Cell & Genetic Therapies) | $240K–$300K | Vertex RSUs | Rare, precedent-setting regulatory experience |
| Executive Director, Clinical Development | $300K–$390K | Vertex RSUs | Bonus target ~25% |
| Director, Global Market Access | $220K–$280K | Vertex RSUs | Rare-disease pricing strategy expertise |
| Director, Cell Therapy Manufacturing | $220K–$290K | Vertex RSUs | Emerging function tied to type 1 diabetes cell therapy pipeline |
Which profiles transfer well, and where
The standout big-pharma-to-biotech-startup transition out of Vertex is a Director from the Cell and Genetic Therapies regulatory group moving to a gene-editing or cell therapy biotech that needs someone who has actually taken a genomic medicine through approval, not just studied the pathway theoretically.
| Origin Team | Strengths | Best-Fit Destination | Watch-Outs |
|---|---|---|---|
| Discovery Chemistry (CFTR modulator legacy) | Iterative small-molecule optimization across multiple compound generations | Biotech tackling a genuinely hard, previously undruggable target | Startup timelines rarely allow for Vertex's multi-generation iteration approach |
| Regulatory Affairs, Cell & Genetic Therapies | Precedent-setting gene-editing regulatory strategy | Gene-editing or cell therapy biotech approaching its first filing | Casgevy's playbook is novel and won't map directly to every modality |
| Rare Disease Market Access | Value-based and outcomes-based pricing negotiation | Biotech launching a high-cost rare-disease therapy | Payer landscape shifts quickly; playbooks need updating per program |
| Cell Therapy Manufacturing (diabetes pipeline) | Emerging allogeneic cell therapy process development | Cell therapy biotech in earlier-stage process development | Function is newer at Vertex itself, so bench depth varies by hire |
How to recruit out of Vertex
Motivators: appetite for new scientific challenges after long CFTR-program tenures, and interest in earlier-stage modalities like gene editing or cell therapy where Vertex is still building its own bench. Blockers: strong mission attachment to the cystic fibrosis community and competitive RSU packages that reward tenure.
Vertex's Boston headquarters is largely on-site, consistent with its lab-intensive discovery culture, so remote flexibility is a genuine differentiator when recruiting away, especially for regulatory and market access roles that don't require bench presence. Counter-offers commonly emphasize movement into the newer cell and gene therapy or pain franchises, giving internal candidates a reason to stay without leaving the company.
Frequently asked questions
Why is Vertex's Casgevy regulatory team so valuable to gene-editing startups?
Casgevy was one of the first commercial CRISPR-based gene-editing therapies to gain approval, so the regulatory affairs staff behind it navigated genuinely novel FDA and EMA review processes. That precedent-setting experience is scarce and highly sought after by earlier-stage gene-editing companies.
How does Vertex's narrow-portfolio structure affect the seniority of its Director-level hires?
Because Vertex runs a genuinely focused portfolio for its size, Directors often carry program-level visibility closer to a smaller biotech's structure than a typical large-pharma matrix, which makes them well-prepared for VP-level scope at a growth-stage company.
What is Vertex's interview process like for discovery chemistry roles?
Expect a data presentation defended in front of a multidisciplinary panel spanning chemistry, biology, and DMPK, with deep questioning on molecule-design tradeoffs across multiple compound generations, reflecting Vertex's iterative approach to its CFTR modulator programs.
Does Vertex pay a premium for cell and gene therapy talent given Casgevy?
Yes, particularly in regulatory affairs and manufacturing roles tied to the Cell and Genetic Therapies unit, where scarce precedent-setting experience commands total comp at the higher end of Vertex's already competitive director-level ranges.
What functions is Vertex expanding beyond cystic fibrosis?
Vertex is actively building out its pain franchise following its non-opioid pain therapy approval, its type 1 diabetes cell therapy pipeline, and its cell and gene therapy commercial infrastructure tied to Casgevy's continued rollout.